KUALA LUMPUR: CCM Duopharma Biotech Bhd
(CCMD) will deliver RM300mil of human insulin to the government over a three-year period under the Health Ministry's off-take agreement programme.
It said on Wednesday the government had acceped the tender offer from Biocon Sdn Bhd to manufacture and supply the insulin. Biocon had appointed its unit CCM Pharmaceuticals Sdn Bhd to be the reseller.
“The letter of award shall be for a period of three years commencing on Dec 2, 2016 until Dec 1, 2019 with a total contract value of RM300.04mil,” CCMD said.
The letter of award will allow CCM Pharmaceuticals to provide the front-end sales, marketing, distribution and support services for the supply of Biocon’s human insulin formulation to all the government's hospitals and Klinik Kesihatan.
“With an estimated 3.5 million diabetics in Malaysia, of which about 350,000 patients are treated using human insulin in government hospitals and clinics.
“Biocon and CCM Pharmaceuticals hope to improve diabetes management in the country by providing high quality and cost effective biosimilar insulins,” CCMD said.
Biocon is a unit of Biocon Biologics Ltd, UK which is in turn a wholly owned subsidiary of Biocon Ltd, India.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
